425: Waters and BD Biosciences & Diagnostic Solutions to Combine in $17.5 Billion Reverse Morris Trust, Creating Life Science and Diagnostics Leader

Waters Corporation and Becton, Dickinson and Company announced a definitive agreement to combine BD's Biosciences & Diagnostic Solutions business with Waters in a $17.5 billion Reverse Morris Trust transaction, forming an innovative life science and diagnostics leader.

Summary

• BD's Biosciences & Diagnostic Solutions business will be combined with Waters Corporation through a tax-efficient Reverse Morris Trust transaction valued at approximately $17.5 billion.
• The combined company will operate under the Waters name, retaining its listing on the New York Stock Exchange under the ticker symbol WAT, with headquarters in Milford, Massachusetts.
• BD shareholders are expected to own approximately 39.2% of the combined company, while existing Waters shareholders are expected to own approximately 60.8%.
• BD will receive a cash distribution of approximately $4 billion prior to the completion of the combination, subject to adjustments for cash, working capital, and indebtedness.
• The transaction is expected to be generally tax-free for U.S. federal income tax purposes to BD and its shareholders.
• The combined entity is projected to achieve pro forma sales of approximately $6.5 billion and adjusted EBITDA of approximately $2.0 billion for calendar year 2025.
• Annualized EBITDA synergies of approximately $345 million are anticipated by 2030, comprising $200 million in cost synergies by year three and $290 million in revenue synergies by year five.
• The transaction is expected to be accretive to adjusted EPS in the first year post-closing.
• The closing is anticipated around the end of the first quarter of calendar year 2026, contingent on regulatory approvals, Waters shareholder approval, and other customary closing conditions.

Sentiment

Score: 9

Explanation: The document presents a highly positive outlook on the proposed transaction, emphasizing significant strategic fit, substantial financial synergies, market expansion, and strong future growth projections for both the combined entity and the 'New BD'. The language consistently highlights 'industry-leading' metrics and 'value creation'.

Positives

• Creates an innovative life science and diagnostics leader with pioneering technologies and an industry-leading financial outlook.
• Doubles Waters' total addressable market to approximately $40 billion, with an anticipated 5-7% annual growth rate.
• Increases annual recurring revenue to over 70% for the combined company, with over 80% of revenue derived from iconic market-leading brands.
• Expected to deliver mid-to-high single-digit revenue growth, approximately 500 basis points of adjusted operating margin expansion, and mid-teens annualized adjusted EPS growth over five years (2025-2030).
• Anticipated to be accretive to adjusted EPS in the first year post-closing.
• Substantial cost synergies of approximately $200 million are expected by year three post-closing, primarily from optimization in manufacturing, supply chain, and SG&A.
• Significant revenue synergies of approximately $290 million are expected by year five, driven by commercial excellence, accelerated expansion into high-growth adjacencies, and cross-selling opportunities.
• BD will receive a cash distribution of approximately $4 billion, enhancing its capital allocation framework, with at least half committed to share repurchases and the remainder for debt repayment.
• The transaction is expected to be generally tax-free for U.S. federal income tax purposes to BD and its shareholders.
• Waters' proven execution model is expected to unlock the full potential of BD's Biosciences & Diagnostic Solutions business.
• The combined company is projected to have a net-debt-to-adjusted EBITDA leverage ratio of 2.3x at closing, expected to decrease to below 2.0x within 18 months.

Risks

• One or more closing conditions, including certain regulatory approvals, may not be satisfied or waived on a timely basis, or a governmental entity may prohibit, delay, or refuse to grant approval, or impose conditions.
• The required approval by the stockholders of Waters may not be obtained.
• The proposed transaction may not be completed on the terms or in the time frame expected, or at all.
• Unexpected costs, charges, or expenses may result from the proposed transaction.
• Uncertainty regarding the expected financial performance of the combined company following completion of the proposed transaction.
• Failure to realize the anticipated benefits of the proposed transaction, including as a result of delays in completion or integration of the businesses.
• Difficulties and delays in the combined company achieving revenue and cost synergies.
• Inability of the combined company to retain and hire key personnel.
• The occurrence of any event that could give rise to termination of the proposed transaction.
• Stockholder litigation or other litigation, settlements, or investigations in connection with the proposed transaction may affect its timing or occurrence or result in significant costs.
• Evolving legal, regulatory, and tax regimes could impact the transaction or combined operations.
• Changes in general economic and/or industry-specific conditions or volatility from tariffs.
• Actions by third parties, including government agencies, could affect the transaction.
• The anticipated tax treatment of the proposed transaction may not be obtained.
• Greater than expected difficulty in separating the business of SpinCo from the other businesses of BD.
• Disruption of management time from ongoing business operations due to the pendency of the proposed transaction.
• Other effects of the pendency of the proposed transaction on relationships with employees, customers, suppliers, or other counterparties.
• Projected financial information for the combined businesses is based on management estimates and assumptions and has not been prepared in conformance with Regulation S-X pro forma financial information requirements.
• The credit ratings of the combined company may decline following the proposed transaction.
• The announcement or consummation of the proposed transaction may have a negative effect on the market price of the capital stock of Waters and BD or on their operating results.

Future Outlook

The combined company is expected to achieve mid-to-high single-digit revenue growth and mid-teens adjusted EPS growth on an annualized basis between 2025 and 2030. By 2030, the pro forma combined company is projected to reach approximately $9 billion in revenue, $3.3 billion in adjusted EBITDA, and an adjusted operating margin of 32%. The transaction is anticipated to be accretive to adjusted EPS in the first year post-closing. The 'New BD' (post-spin) is expected to be a pure-play medical technology company with a $70+ billion addressable market growing at approximately 5%, aiming for mid-single-digit revenue growth and strong earnings growth, supported by approximately $1 billion in annual R&D investment.

Management Comments

• "This transaction marks a pivotal milestone in Waters' transformation journey as we embark on a new chapter of growth and value creation." Flemming Ornskov, M.D., M.P.H., Chairman, Waters.
• "Waters' transformation, marked by strong commercial execution and revitalized innovation, positions us well for this exciting next chapter. We see tremendous opportunity to immediately apply our expertise in instrument replacement, service plan attachment, and eCommerce expansion, and realize the full potential of the flow cytometry and specialty diagnostics portfolios." Udit Batra, Ph.D., President and Chief Executive Officer, Waters.
• "We are bringing together complementary portfolios and channels that create an industry-leading life science and diagnostics company. We see an incredible opportunity to leverage both companies' commitments to unparalleled innovation, technology, and commercial presence to serve attractive high-growth end-markets, while simultaneously unlocking multiple new growth vectors." Tom Polen, Chairman, CEO and President, BD.
• "This transaction is an important milestone for BD, as it enhances our strategic focus as a leading medical technology company. BD is committed to unlocking long-term value through continued investment in our strong innovation pipeline, and operational and commercial excellence that will drive durable and profitable growth." Tom Polen, Chairman, CEO and President, BD.

Industry Context

The transaction creates a combined entity focused on regulated, high-volume testing within the life science and diagnostics sectors. It aims to capitalize on high-growth adjacencies like bioseparations, bioanalytical characterization, and multiplex diagnostics, driven by increasing testing requirements in pharmaceuticals, food, environmental, and clinical settings. This move reflects a broader trend of consolidation and specialization within the medical technology and life science tools industries, seeking to leverage complementary technologies and market access for enhanced growth and efficiency.

Comparison to Industry Standards

• The combined company is expected to have an "industry-leading financial outlook" with mid-to-high single-digit revenue growth, approximately 500 basis points of adjusted operating margin expansion, and mid-teens annualized adjusted EPS growth expected over five years.
• Waters' standalone adjusted EBITDA margin of 37% and FCF as % of revenue of 37% for Calendar Year 2024 are noted as higher than the peer average (27% and 18% respectively for companies like Agilent Technologies (A), Avantor (AVTR), Danaher (DHR), Revvity (RVTY), and Thermo Fisher Scientific (TMO)).
• Waters has the highest service satisfaction score among all instrument vendors and a tNPS score over 20 points higher than the benchmark average, according to SDi 2024 Analytical & Life Science Instrumentation Service Market and Technology Services Industry Association (TSIA) 2024.
• The 'New BD' (post-transaction) is expected to maintain a 'best-in-class consumables revenue profile of over 90%'.
• Waters' Empower informatics platform is used for approximately 80% of novel drugs submitted to FDA, EMA, and China NMPA, indicating a strong market position in compliant informatics.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders (BD): Expected to own approximately 39.2% of the combined company, participate in upside value creation from transaction synergies and growth opportunities, and benefit from a $4 billion cash distribution (with at least half allocated to share repurchases).
• Shareholders (Waters): Expected to own approximately 60.8% of the combined company, benefiting from doubled addressable market, increased recurring revenue, and significant synergies.
• Employees (BD Biosciences & Diagnostic Solutions): Waters is stated to offer the 'right cultural fit' for associates to flourish and continue their legacy, with executives from both companies serving in key leadership roles.
• Customers: Expected to benefit from complementary technologies, enhanced market access, improved service support, accelerated menu expansion, and automation for multiplex diagnostics.
• Creditors: Waters is expected to assume approximately $4 billion of incremental debt, impacting the combined company's leverage ratio (2.3x at closing, aiming for <2.0x within 18 months).

Next Steps

• Filing of relevant materials with the SEC, including a registration statement on Form S-4 by Waters and a registration statement on Form 10 by SpinCo.
• Waters shareholder approval for the transaction.
• Receipt of required regulatory approvals.
• Satisfaction of other customary closing conditions.
• Closing of the transaction around the end of the first quarter of calendar year 2026.
• Announcement of key leadership roles from both companies at a later date.
• BD to share more information regarding New BD's go-forward strategy, deep innovation pipeline, and longer-term financial outlook closer to the completion of this transaction.

Key Dates

Recommendation

Keywords

Life Science, Diagnostics, Medical Technology, Reverse Morris Trust, Merger, Acquisition, Spin-off, Waters Corporation, Becton Dickinson, BDX, WAT, Flow Cytometry, Mass Spectrometry, Liquid Chromatography, Bioseparations, Bioanalytical Characterization, Multiplex Diagnostics, Healthcare, Biopharma, Clinical Diagnostics, Laboratory Automation, SEC Filing